人体内肺癌细胞Ku80蛋白含量与顺铂化疗敏感性的关系研究

Relationship Between Ku80 Protein Content and Sensitivity to Cisplatin of Human Lung Cancer Cells

目的探讨患者体内肺癌细胞Ku80蛋白含量与其对顺铂敏感性的相关性。方法收集肺癌患者胸腔积液中的肺癌细胞进行体外原代培养,通过传代进行纯化和扩增后进行实验。体外药敏试验采用CCK-8法测定肺癌细胞对顺铂的敏感性,获得各样本的半数抑制浓度(IC50)。利用Western blot法测定各样本细胞内Ku80蛋白含量。分析Ku80蛋白含量与顺铂敏感性的相关性。结果非小细胞肺癌(NSCLC)组IC50为(4.40±3.39)mg/L,小细胞肺癌(SCLC)组IC50为(1.02±0.54)mg/L,二者比较差异有统计学意义(P<0.001)。NSCLC组Ku80蛋白相对含量为0.80±0.45,而SCLC组为0.48±0.25,二组之间比较差异有统计学意义(P<0.05)。通过相关性分析得到肺癌患者Ku80含量与IC50呈正相关(r=0.618,P<0.001)。结论 NSCLC患者Ku80基因表达高于SCLC患者,可能与NSCLC对化疗敏感性差有关。肺癌细胞Ku80蛋白含量与其对顺铂敏感性呈负相关。Ku80蛋白含量可作为预测肺癌患者以铂类为基础的化疗敏感性的候选指标。

Objective Non-small cell lung cancer（NSCLC） cells are relatively resistant to chemotherapy,and the outcomes are not always satisfactory.This study was designed to explore the relationship between the content of Ku80 protein of human lung cancer cells and their sensitivity to cisplatin.Methods The lung cancer cells isolated from malignant pleural effusion samples from patients with primary lung cancer were cultured in vitro.The sensitivity to cisplatin was tested with the method of CCK-8 expressed as half maximal inhibitory concentration（IC50）.The relative content of Ku80 protein was determined by Western blot.The correlation between sensitivity to cisplatin of lung cancer cells and the relative content of Ku80 protein was analyzed.Results The IC50 of NSCLC group was significantly higher than that of SCLC group [（4.40±3.39）mg/L vs.（1.02±0.54）mg/L,P0.001].The relative content of Ku80 protein of NSCLC group was statistically higher than that of SCLC group [（0.80±0.45） vs.（0.48±0.25）,P0.05].The correlation coefficient between content of Ku80 protein and IC50 was 0.618（P0.001）.Conclusions The content of Ku80 protein of NSCLC patients is higher than that of SCLC patients.It may be one of the mechanisms contributing to chemotherapeutic resistance of NSCLC.There is a negative relationship between Ku80 protein content of cancer cells and their sensitivity to cisplatin suggesting that the content of Ku80 protein may be served as a candidate index for predicting sensitivity of lung cancer cells to cisplatin.